As­traZeneca, Am­gen tout PhI­II win for 'break­through' asth­ma drug, check­ing a block­buster box that Dupix­ent did­n't

5 years ago
R&D

FDA hits Su­per­nus with dou­ble wham­my, hand­ing biotech a CRL and RTF on same day

5 years ago
FDA+

Vivek Ra­maswamy eyes an I/O vant with up to $2B li­cens­ing deal

5 years ago
People
Deals

Mer­ck pulls the plug on a study eval­u­at­ing block­buster Keytru­da with Yer­voy for NSCLC

5 years ago
R&D

In an­oth­er win for mR­NA, Cure­Vac ex­ecs de­tail the new PhI read­out of their vac­cine da­ta and why they’re so pumped ...

5 years ago
R&D

News brief­ing: Lo­cus Bio­sciences bags up to $12.1M for CRISPR an­tibac­te­r­i­al; Old Ver­tex drug heads to PhI­II for ...

5 years ago
News Briefing

'We're not a van­t': Ax­o­vant seeks to for­get the past as the com­pa­ny re­brands to Sio Gene Ther­a­pies

5 years ago
People
Cell/Gene Tx

GV steps up to back Till­man Gern­gross’ new an­ti­body play against Covid-19 — and he’s al­ready think­ing about the ...

5 years ago
Financing
Coronavirus

DSMB hits pause on Voy­ager's Neu­ro­crine-part­nered Parkin­son's gene ther­a­py

5 years ago
Cell/Gene Tx

Covid-19 roundup: With ef­fi­ca­cy da­ta in hand, BioN­Tech talks pric­ing; Brazil halts Sino­vac tri­al fol­low­ing pa­tient ...

5 years ago
FDA+
Coronavirus

Sweep­ing doubts aside, Eli Lil­ly beats Re­gen­eron to emer­gency OK — clear­ing low dose an­ti­body for quick roll­out

5 years ago
FDA+
Coronavirus

Are­na's lead drug miss­es on PhII in AD, thwack­ing stock, but com­pa­ny sol­diers on in­to Phase III

5 years ago
R&D

Pfiz­er-BioN­Tech da­ta lift glob­al faith in Covid-19 vac­cines, but set 'ex­treme­ly high bar' for com­peti­tors

5 years ago
Coronavirus

News brief­ing: In­tel­lia hits clin­ic with CRISPR ther­a­py; Vi­for con­tin­ues to spend, pay­ing up to $340M for DGF pro­gram

5 years ago
News Briefing

Bris­tol My­ers posts an­oth­er win for their Ote­zla com­peti­tor, this time with PhII da­ta in pso­ri­at­ic arthri­tis

5 years ago
R&D
Pharma

Leg­end Biotech has a new chair­woman and per­ma­nent CEO. But where is Frank Zhang?

5 years ago
People
Cell/Gene Tx

Prometheus Bio is ready for its close-up shot, fol­low­ing a $130M round to back IBD drugs now head­ed to the clin­ic

5 years ago
Financing

Covid-19 roundup: Biden out­lines virus plan, names Rick Bright to task force; Arc­turus reads out pos­i­tive Phase I/II ...

5 years ago
Coronavirus

GSK re­ports its long-act­ing HIV PrEP tops Gilead­'s Tru­va­da — again

5 years ago
R&D

Pfiz­er, BioN­Tech say Covid-19 vac­cine is more than 90% ef­fec­tive, ex­ceed­ing ex­pert ex­pec­ta­tions and set­ting up an EUA ...

5 years ago
Coronavirus

New­ly Nas­daq-list­ed Cal­lid­i­tas surges af­ter lead kid­ney drug hits pri­ma­ry end­point

5 years ago
R&D

Deci­bel Ther­a­peu­tics rais­es $82M as Lau­rence Reid looks to steer gene ther­a­py piv­ot

5 years ago
Startups
Cell/Gene Tx

Now that Bio­gen’s ad­u­canum­ab team and the FDA’s Bil­ly Dunn have been bat­tered by a gamut of an­gry ex­perts, the ...

5 years ago
FDA+

Ex­pert pan­el re­view on Alzheimer’s drug ad­u­canum­ab be­comes a one-day tri­al by fire as crit­ics turn their guns on ...

5 years ago
FDA+
First page Previous page 779780781782783784785 Next page Last page
A service from the Financial Times